LRMR — Larimar Therapeutics Share News
0.000.00%
Last trade - 00:00- $313.73m
- $157.46m
Larimar Therapeutics Inc expected to post a loss of 32 cents a share - Earnings Preview
Brief: Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia
Brief: Larimar Therapeutics Announces Positive Initial Data From Ongoing Long-Term Open Label Extension Study
Brief: Larimar Therapeutics Q3 Net Income USD -15.499 Million
U.S. RESEARCH ROUNDUP-Array Technologies, Hess, Lennar
Larimar Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Larimar Therapeutics Q2 Net Income USD -21.627 Million
Larimar Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Larimar Therapeutics Inc Selected By FDA To Participate In Start Pilot Program For Nomlabofusp In Friedreich's Ataxia
U.S. STOCKS ON THE MOVE-ProShares Ether, International Business Machines, Alvotech
U.S. STOCKS ON THE MOVE-Durect, Mangoceuticals, International Business Machines
U.S. STOCKS ON THE MOVE-Nikola, Citius Pharmaceuticals, Full Truck Alliance
U.S. STOCKS ON THE MOVE-Larimar Therapeutics, Xpeng, Lowe's
Larimar soars as FDA removes partial clinical hold on genetic disease therapy
Brief: Larimar Therapeutics Announces FDA Has Removed Partial Clinical Hold For Nomlabofusp Program In Friedreich’S Ataxia
Larimar Therapeutics rises as US FDA removes partial clinical hold on genetic disease therapy
Larimar Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Larimar Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Larimar Therapeutics Files For Mixed Shelf Of Up To $300 Mln